Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Downgrades Baxter Intl to Equal-Weight, Announces $55 Price Target

Morgan Stanley analyst Cecilia Furlong downgrades Baxter Intl (NYSE:BAX) from Overweight to Equal-Weight and announces $55 price target.
byBenzinga Newsdesk
January 6, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Morgan Stanley analyst Cecilia Furlong downgrades Baxter Intl (NYSE:BAX) from Overweight to Equal-Weight and announces $55 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Precigen To Present Late-Breaking Abstract For Pivotal Phase 2 Study Data For PRGN-2012 AdenoVerse Immunotherapy For The Treatment Of Patients With Recurrent Respiratory Papillomatosis At The 2024 ASCO Annual Meeting

By Benzinga Newsdesk
April 24, 10:22 AM
Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data from the pivotal Phase

PGEN